ArticleAnnals of the rheumatic diseases2024
Rheumatology and Long COVID: lessons from the study of fibromyalgia.
Article in Annals of the rheumatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- New Onset of Fibromyalgia After Exposure to a Combat Environment: A Longitudinal Cohort Study.Arthritis care & research · 2026Article
- Meditations on Methodological Issues in Clinical Investigations of "Central Sensitization" (Jonah XII).Journal of clinical medicine · 2026Article
- Understanding fibromyalgia beyond pain: emotional imbalance and the case for compassionate care.RMD open · 2026Review
- A systematic scoping review and conceptual analysis of new-onset fibromyalgia manifestations after non-hospitalized COVID-19: empirics, definitions, methodologies, pathophysiology, mapping of literature, and knowledge gaps.Journal of translational medicine · 2026Article
- Long-term examination of pain and health-related outcomes in people with fibromyalgia before, during, and after COVID-19.Pain reports · 2026Article
- Association Between Post-COVID-19 Infection and Fibromyalgia: A Controlled Case-Control Study.Journal of clinical medicine · 2026Article
- Prior COVID-19 infection and fibromyalgia criteria fulfillment: a comparative cross-sectional study.Frontiers in medicine · 2026Article
- Association between bruxism and inflammatory rheumatic diseases: is there a possible bidirectional relationship?Rheumatology international · 2025Review
- Mu-opioid receptor expression on B cells as a potential biomarker for chronic pain: a follow-up study with patients with fibromyalgia.Pain reports · 2025Article
- "A Light at the End of the Tunnel"-Post-COVID Condition and the Role of Rehabilitation and Recovery Intervention Delivered in a Football Club Community Trust: A Qualitative Study.Healthcare (Basel, Switzerland) · 2025Article
- The National Academies' 2024 Diagnostic Criteria for Long COVID: Concerns That Could Affect the Rheumatology Community.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Fibromyalgia: are you a genetic/environmental disease?Pain reports · 2025Review
- HERV activation segregates ME/CFS from fibromyalgia while defining a novel nosologic entity.eLife · 2025Article
- [Chronic pain syndrome in musculoskeletal diseases-how different are fibromyalgia and long Covid?-Part 1].Zeitschrift fur Rheumatologie · 2025Review
- mTORC1 syndrome (TorS): unifying paradigm for PASC, ME/CFS and PAIS.Journal of translational medicine · 2025Review
- Inflammation, Autoimmunity, and Infection in Fibromyalgia: A Narrative Review.International journal of molecular sciences · 2024Review
- Article
- Long COVID-19 Enigma: Unmasking the Role of Distinctive Personality Profiles as Risk Factors.Journal of clinical medicine · 2024Article
- What the SARS-CoV-2 Pandemic Has Taught Us About Immunosuppression, Vaccinations, and Immune Dysregulation: The Rheumatology Experience.Current allergy and asthma reports · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatology, such as other subspecialties, has both a unique perspective to offer as well as an evolving role to play in the global COVID-19 pandemic. Our field has already contributed meaningfully to the development and repurposing of many of the immune-based therapeutics which are now standard treatments for severe forms of the disease as well as to the understanding of the epidemiology, risk factors and natural history of COVID-19 in immune-mediated inflammatory diseases. Still in evolution is our potential to contribute to burgeoning research efforts in the next phase of the pandemic: the syndrome of postacute sequelae of COVID-19 or Long COVID. While our field brings many assets to the study of Long COVID including our expertise in the investigation of chronic inflammation and autoimmunity, our Viewpoint focuses on the strong similarities between fibromyalgia (FM) and Long COVID. While one can speculate on how embracing and confident practising rheumatologists already are regarding these interrelationships, we assert that in the emerging field of Long COVID the potential lessons from the field of fibromyalgia care and research have been underappreciated and marginalised and most importantly now deserve a critical appraisal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.